The clinical paper about Medytox's hyaluronic acid filler 'Neuramis' was published in a SCIE-level international academic journal, proving its efficacy and safety in restoring the volume of the center of the face.
Medytox announced that a comparative clinical research paper proving the efficacy and safety of 'Neuramis Volume Lidocaine' conducted for Asians was published in the latest issue of the international scientific journal 'European Journal of Beauty and Dermatology'. ‘European Journal of Aesthetic and Dermatology’ is an internationally renowned journal listed in the Scientific and Technical Papers Additional Citation Index (SCIE).
This clinical paper, a joint study between Department of Dermatology, Ulsan University of Medicine and Department of Dermatology, Chung-Ang University Hospital, was randomized to 88 adults who needed correction due to a decrease in the volume of the mid-facial area (cheek area, anterior medial cheek area, and lower cheek area) with moderate or more severe symptoms. According to the allocation method, 'Neuramis Volume Lidocaine' or 'Juvederm Voluma with Lidocaine (Allergan, USA)' was injected into the right and left sides of the subject's central facial area, respectively.
As a result, the improvement rate of the subjects at 24 weeks according to the Mid-Face Volume Deficit Scale (MFVDS), a measure of the degree of volume recovery in the center of the face, was 96.4%, which was the same for both the test group and the control group. The satisfaction of the subjects at 24 weeks according to the Global Aesthetic Improvement Scale (GAIS) was also 100% in both the test group and the control group.
The core researcher of this study said, “This clinical trial is significant in that it confirmed the efficacy and safety of the most important product when selecting a filler. I think it has been proven that we are not left behind even by comparison.”
See this product: https://www.koreabeautytech.com/search?type=product%2Cpage%2Carticle&q=neuramis
